Breaking News, Financial News

Axol Bioscience Secures $2.8M for U.S. Expansion, Product Development

Financing was led by BroadOak Capital Partners, a U.S. life sciences specialist.

Author Image

By: Patrick Lavery

Content Marketing Editor

UK-based Axol Bioscience has raised $2.8 million (£2.1 million) in funding to accelerate expansion of U.S. operations and development. The investment was led by BroadOak Capital Partners, a U.S. life sciences specialist, and joined by founding investor The Roslin Foundation. Axol provides induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research. Expanding Axol’s U.S. operations and commercial presence, the company said, will enable development of enha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters